argenx SE – (NASDAQ:ARGX) has received a consensus rating of “Buy” from the eight research firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $132.00.

A number of equities research analysts have commented on ARGX shares. Cowen reiterated a “buy” rating on shares of argenx in a report on Thursday, June 14th. Nomura started coverage on argenx in a report on Friday, June 29th. They set a “buy” rating and a $161.00 target price on the stock. ValuEngine upgraded argenx from a “hold” rating to a “buy” rating in a report on Friday, June 1st. Zacks Investment Research upgraded argenx from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Finally, Wedbush reiterated an “outperform” rating and set a $92.00 target price (down previously from $93.00) on shares of argenx in a report on Thursday, May 10th.

Several hedge funds have recently bought and sold shares of the company. Granahan Investment Management Inc. MA boosted its holdings in shares of argenx by 102.6% during the second quarter. Granahan Investment Management Inc. MA now owns 95,419 shares of the company’s stock worth $7,906,000 after purchasing an additional 48,319 shares during the last quarter. Orbimed Advisors LLC boosted its holdings in shares of argenx by 19.9% during the second quarter. Orbimed Advisors LLC now owns 599,300 shares of the company’s stock worth $49,658,000 after purchasing an additional 99,300 shares during the last quarter. Acuta Capital Partners LLC boosted its holdings in shares of argenx by 12.2% during the second quarter. Acuta Capital Partners LLC now owns 453,233 shares of the company’s stock worth $37,555,000 after purchasing an additional 49,412 shares during the last quarter. Redmile Group LLC boosted its holdings in shares of argenx by 182.2% during the second quarter. Redmile Group LLC now owns 673,300 shares of the company’s stock worth $55,790,000 after purchasing an additional 434,700 shares during the last quarter. Finally, Point72 Asset Management L.P. boosted its holdings in shares of argenx by 18.3% during the second quarter. Point72 Asset Management L.P. now owns 70,978 shares of the company’s stock worth $5,881,000 after purchasing an additional 10,978 shares during the last quarter. Institutional investors and hedge funds own 53.25% of the company’s stock.

NASDAQ ARGX traded up $1.29 during mid-day trading on Friday, hitting $84.94. The stock had a trading volume of 102,200 shares, compared to its average volume of 141,185. argenx has a 52-week low of $20.10 and a 52-week high of $103.00. The company has a market capitalization of $2.89 billion, a P/E ratio of -59.83 and a beta of 2.42.

About argenx

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Further Reading: Outstanding Shares

Analyst Recommendations for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.